Transient abnormal myelopoiesis of infancy associated with trisomy 21.

A C Homans, A M Verissimo, V Vlacha
{"title":"Transient abnormal myelopoiesis of infancy associated with trisomy 21.","authors":"A C Homans,&nbsp;A M Verissimo,&nbsp;V Vlacha","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>A unique myelodysplastic syndrome referred to as transient abnormal myelopoiesis (TAM) has been reported to occur primarily in infants with Down's syndrome (DS) or other abnormalities of chromosome 21. This disorder raises basic questions regarding the pathogenesis of leukemia, yet its natural history is poorly documented and derives from small series and isolated case reports.</p><p><strong>Patients and methods: </strong>To better characterize TAM, we accumulated data on 35 cases identified through a questionnaire mailed to pediatric oncologists in the United States. These cases, pooled with two that we recently encountered, and 58 comparable cases reported in the literature comprise a series of 95 cases of TAM in DS.</p><p><strong>Results: </strong>The patients in this series were notable for the high morbidity and mortality of this reportedly benign condition. Eleven percent of the patients died during the initial event, and the overall mortality for the entire series was 27%. Twenty-eight of the 85 patients (33%) who survived the initial event developed a subsequent hematologic disorder, most often acute nonlymphocytic leukemia, at a median age of 16 months.</p><p><strong>Conclusions: </strong>No initial clinical or hematologic features predicted the development of a subsequent hematologic disorder. However, those patients initially mosaic for the presence of trisomy 21 did not develop subsequent abnormalities. This series reviews questions regarding leukemogenesis in DS and underscores the importance of conducting future prospective studies of this unique hematologic disorder.</p>","PeriodicalId":22558,"journal":{"name":"The American journal of pediatric hematology/oncology","volume":"15 4","pages":"392-9"},"PeriodicalIF":0.0000,"publicationDate":"1993-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The American journal of pediatric hematology/oncology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: A unique myelodysplastic syndrome referred to as transient abnormal myelopoiesis (TAM) has been reported to occur primarily in infants with Down's syndrome (DS) or other abnormalities of chromosome 21. This disorder raises basic questions regarding the pathogenesis of leukemia, yet its natural history is poorly documented and derives from small series and isolated case reports.

Patients and methods: To better characterize TAM, we accumulated data on 35 cases identified through a questionnaire mailed to pediatric oncologists in the United States. These cases, pooled with two that we recently encountered, and 58 comparable cases reported in the literature comprise a series of 95 cases of TAM in DS.

Results: The patients in this series were notable for the high morbidity and mortality of this reportedly benign condition. Eleven percent of the patients died during the initial event, and the overall mortality for the entire series was 27%. Twenty-eight of the 85 patients (33%) who survived the initial event developed a subsequent hematologic disorder, most often acute nonlymphocytic leukemia, at a median age of 16 months.

Conclusions: No initial clinical or hematologic features predicted the development of a subsequent hematologic disorder. However, those patients initially mosaic for the presence of trisomy 21 did not develop subsequent abnormalities. This series reviews questions regarding leukemogenesis in DS and underscores the importance of conducting future prospective studies of this unique hematologic disorder.

与21三体相关的婴儿短暂性骨髓异常。
目的:一种独特的骨髓增生异常综合征被称为短暂性骨髓增生异常(TAM),主要发生在患有唐氏综合征(DS)或其他21号染色体异常的婴儿身上。这种疾病提出了关于白血病发病机制的基本问题,但其自然史文献很少,并且来自小系列和孤立病例报告。患者和方法:为了更好地描述TAM,我们收集了通过邮寄给美国儿科肿瘤学家的问卷调查确定的35例病例的数据。这些病例,加上我们最近遇到的两例,以及文献中报道的58例可比病例,构成了DS中95例TAM的一系列病例。结果:本系列患者的发病率和死亡率都很高,这是一种良性疾病。11%的患者在最初的事件中死亡,整个系列的总死亡率为27%。85例患者中有28例(33%)在初始事件中存活,随后发展为血液系统疾病,最常见的是急性非淋巴细胞白血病,中位年龄为16个月。结论:没有最初的临床或血液学特征预测后续血液学疾病的发展。然而,那些最初因21三体存在而镶嵌的患者并没有出现随后的异常。本系列回顾了有关DS中白血病发生的问题,并强调了对这种独特的血液系统疾病进行未来前瞻性研究的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信